Liver Cancer Treatment in India for Ghanaian Patients 2026 — Surgery, TACE, Transplant, Costs and Complete Guide

Complete 2026 guide to liver cancer treatment in India for Ghanaian patients. Covers hepatocellular carcinoma, BCLC staging, liver resection, TACE, Y-90 radioembolisation, liver transplant, targeted therapy, costs, and free specialist review within 48 hours.

Liver cancer carries a particular weight in Ghana that it does not carry in most other parts of the world. Ghana has one of the highest rates of hepatitis B infection in sub-Saharan Africa — a chronic viral infection that, when left untreated over years and decades, damages the liver progressively and significantly raises the risk of developing hepatocellular carcinoma, the most common form of primary liver cancer. The connection between hepatitis B and liver cancer is direct, well-established, and deeply relevant to Ghanaian patients: a significant proportion of liver cancer cases diagnosed in Ghana occur in people who have been living with chronic hepatitis B infection, often without knowing the full implications of that infection for their long-term health.

This context matters for two reasons. First, it means that liver cancer in Ghana is often diagnosed in people who are relatively young — in their forties and fifties — rather than in the older age groups where it more commonly presents in Western populations. Second, it means that the liver in which the cancer is growing has often been damaged by years of hepatitis B infection and the cirrhosis it causes, which significantly affects what treatment options are available and how the liver will respond to them.

Understanding this background is the starting point for understanding why liver cancer treatment in Ghana is so limited, why India offers genuinely different possibilities, and what Ghanaian patients and their families need to know before making decisions about treatment.

Understanding Liver Cancer — Primary and Secondary, and Why the Distinction Matters

When doctors talk about liver cancer, they are usually referring to one of two very different situations, and distinguishing between them is the first step in understanding treatment.

Primary liver cancer — cancer that starts in the liver cells themselves — is what most Ghanaian patients are dealing with when they receive a liver cancer diagnosis. The most common type of primary liver cancer is hepatocellular carcinoma (HCC), which develops from the main liver cells called hepatocytes. A less common type is intrahepatic cholangiocarcinoma, which develops from the bile duct cells within the liver. Primary liver cancer in Ghana is predominantly HCC, and the vast majority of cases occur in the context of chronic hepatitis B infection and cirrhosis.

Secondary liver cancer — also called liver metastases — is cancer that has spread to the liver from another primary site, most commonly the colon and rectum, breast, lung, or stomach. Liver metastases are treated differently from primary liver cancer, and the treatment approach depends primarily on the nature and extent of the original primary cancer. If you have been told you have cancer in your liver, it is essential to establish clearly whether it is primary liver cancer or metastases from another site — the two situations require completely different management.

This guide focuses primarily on primary liver cancer — hepatocellular carcinoma — because this is the situation most relevant to Ghanaian patients. However, Indian hospitals treat both primary liver cancer and liver metastases from colorectal and other primary cancers, and our team can advise on both situations.

How Liver Cancer Is Diagnosed and Staged — What Your Reports Mean

Liver cancer diagnosis in Ghana is often made on the basis of imaging — an ultrasound or CT scan showing a mass in the liver — combined with a blood test measuring alpha-fetoprotein (AFP), a protein that is elevated in the majority of HCC cases. In patients with known chronic hepatitis B infection and cirrhosis, a characteristic appearance on contrast-enhanced CT or MRI imaging is often sufficient to diagnose HCC without a biopsy, using internationally recognised criteria called LI-RADS or BCLC criteria.

AFP — Alpha-Fetoprotein is the most commonly used blood marker for HCC. A significantly elevated AFP in a patient with chronic hepatitis B and a liver mass is strongly suggestive of HCC. AFP is also used to monitor treatment response and detect recurrence after treatment.

Imaging — contrast-enhanced CT of the liver and chest, and MRI of the liver with hepatobiliary contrast agents — provides the most important information about the tumour: its size, its location within the liver, whether it involves major blood vessels, whether there are multiple tumours, and whether the cancer has spread to lymph nodes or other organs. The quality and completeness of the imaging performed before any treatment decision is made is critically important — inadequate imaging leads to inadequate staging which leads to the wrong treatment.

Liver function assessment is as important as tumour staging for liver cancer patients, because the liver in which the cancer is growing is often damaged by cirrhosis. The Child-Pugh score and the MELD score are the two most commonly used systems for assessing liver function in the context of liver disease. Understanding your liver function status — whether your liver is compensated (functioning adequately despite damage) or decompensated (failing) — determines which treatment options are safe and feasible for your individual case.

The BCLC staging system — Barcelona Clinic Liver Cancer staging — is the most widely used staging system for HCC internationally and is used at all the Indian centres we work with. It integrates tumour size and number, vascular invasion, distant spread, and liver function status into a single staging classification that directly guides treatment recommendations. BCLC stage 0 and A represent early HCC with the best treatment options and outcomes. BCLC stage B represents intermediate HCC. BCLC stage C represents advanced HCC with vascular invasion or distant spread. BCLC stage D represents end-stage disease where the focus shifts to symptom management.

Treatment Options for Liver Cancer in India — A Complete Overview

The range of treatment options for liver cancer in India covers the full spectrum from curative surgical approaches for early disease through to palliative systemic therapy for advanced disease. The most appropriate treatment for any individual patient depends on the BCLC stage, the liver function status, the tumour characteristics, and — increasingly — the molecular profile of the tumour.

Surgical Resection — The Best Chance of Cure for Early HCC

Surgical removal of the tumour — hepatic resection — is the treatment that offers the best long-term outcomes for patients with early-stage HCC and adequate liver function. The operation involves removing the portion of the liver containing the tumour, along with a margin of surrounding normal tissue, while preserving enough functional liver tissue to sustain life.

The liver is unique among solid organs in its ability to regenerate. After resection of up to 70 percent of the liver volume in a patient with normal liver function, the remaining liver tissue grows back to near-normal volume over weeks to months. In patients with cirrhosis — which is the situation for most Ghanaian HCC patients — this regenerative capacity is reduced, and the extent of safe resection is more limited.

For Ghanaian patients to be candidates for surgical resection, several conditions need to be met: the tumour must be accessible to surgical removal, the remaining liver after resection must be sufficient to maintain life, and the liver function must be adequate — generally Child-Pugh class A or well-compensated B. Patients whose liver function is significantly impaired by cirrhosis may not be safe candidates for resection even if the tumour itself is technically resectable.

Indian surgical centres — Tata Memorial, Medanta, Fortis, Apollo, and Max — all have experienced hepatobiliary surgical teams who regularly perform major liver resections for HCC. The ability to perform complex hepatobiliary surgery safely requires not just a skilled surgeon but the supporting infrastructure of anaesthesia, intensive care, interventional radiology, and gastroenterology that major Indian hospitals have in place.

Cost of liver resection in India — 2026:

Minor liver resection (wedge resection or single segment): $6,000 to $9,000. Major liver resection (two or more segments): $9,000 to $15,000. Extended liver resection (more than 60 percent of liver volume): $12,000 to $20,000. These costs include the surgeon's fee, anaesthesia, operating theatre, ICU stay of two to five days, general ward stay of seven to ten days, and standard post-operative monitoring before discharge.

Liver Transplantation — The Treatment That Addresses Both the Cancer and the Cirrhosis

Liver transplantation occupies a unique position in HCC treatment because it is the only approach that simultaneously addresses both the cancer and the underlying cirrhotic liver in which it has developed. By replacing the diseased liver with a healthy donor liver, transplantation removes all tumour tissue — including any microscopic satellite tumours that imaging cannot detect — and eliminates the cirrhotic liver that would otherwise remain a field at risk for new tumour development.

The internationally accepted criteria for liver transplantation in HCC — the Milan Criteria — define the tumour characteristics within which transplantation offers outcomes equivalent to transplantation for non-malignant liver disease. The Milan Criteria specify a single tumour of 5 centimetres or less, or up to three tumours each 3 centimetres or less, without vascular invasion or distant metastases. Patients who meet Milan Criteria and who are otherwise fit for transplantation have five-year survival rates after transplant that exceed 70 percent at experienced centres.

India has a living donor liver transplant programme that is among the most active and experienced in Asia. Because deceased donor organ availability is limited in India — as it is in most countries — the majority of liver transplants performed are living donor transplants, in which a portion of the liver from a healthy living donor — typically a family member — is used. The donor's liver regenerates to near-normal volume within weeks, making living donor transplantation safe for both donor and recipient when performed at experienced centres with appropriate donor evaluation.

For Ghanaian patients, living donor transplantation has a practical advantage over deceased donor transplantation — it does not depend on the availability of a deceased donor organ, which in India can involve a long wait. A family member travelling from Ghana to donate is logistically more complex than using a local donor, but it is entirely feasible and is a pathway our team has supported for African patients before.

Cost of liver transplantation in India — 2026:

Living donor liver transplant (all-inclusive, covering both donor and recipient surgery and hospitalisation): $35,000 to $55,000. This represents one of the most significant cost advantages India offers for any medical procedure — the same procedure costs $300,000 to $500,000 in the United States and £200,000 to £350,000 in the United Kingdom as a private patient. For a Ghanaian family facing an HCC diagnosis in a patient who meets transplant criteria, India is realistically the only financially accessible route to this potentially curative treatment.

TACE — Transarterial Chemoembolisation — For Intermediate Stage HCC

TACE is an interventional radiology procedure — performed not by a surgeon but by a specialist in image-guided procedures — that delivers chemotherapy directly into the blood vessels feeding the tumour while simultaneously blocking those blood vessels to cut off the tumour's blood supply. The combination of concentrated local chemotherapy and arterial occlusion is highly effective at controlling intermediate-stage HCC tumours that are too large or too numerous for surgical resection but have not yet spread beyond the liver.

The procedure is performed under sedation. A thin catheter is inserted through the groin artery, guided under X-ray imaging through the arterial system to the hepatic artery — the main artery supplying blood to the liver — and then advanced selectively into the branch of that artery feeding the tumour. The chemotherapy and embolic material are then injected through the catheter directly into the tumour's blood supply.

Most patients stay in hospital for two to three days after each TACE procedure. Side effects include post-embolisation syndrome — fever, abdominal pain, and fatigue lasting several days — which is expected and managed with medication. TACE is typically repeated every two to three months, and the response is monitored with imaging after each procedure.

For patients being considered for liver transplantation who meet Milan Criteria but face a wait before transplant, TACE is used to keep the tumour within Milan Criteria during the waiting period — a strategy called bridging to transplant. For patients who initially exceed Milan Criteria, sequential TACE can sometimes shrink the tumour sufficiently to meet criteria — a strategy called downstaging to transplant.

Cost of TACE in India — 2026:

Single TACE procedure: $3,500 to $6,000. Drug-eluting bead TACE (DEB-TACE), which uses beads loaded with chemotherapy for more sustained drug release: $5,000 to $8,000 per procedure. For patients requiring multiple TACE sessions — which is the typical situation — the total cost of a TACE-based treatment programme depends on the number of sessions required, which varies between patients.

TARE — Transarterial Radioembolisation (Y-90) — An Advanced Alternative to TACE

TARE — also called selective internal radiation therapy or SIRT — is a more advanced interventional procedure that delivers radioactive microspheres loaded with yttrium-90 (Y-90) directly into the tumour's blood supply. Unlike TACE, which works through a combination of chemotherapy and arterial occlusion, TARE works primarily through the delivery of internal radiation — the Y-90 microspheres lodge in the small vessels within the tumour and emit radiation locally over approximately two weeks.

TARE has several advantages over TACE in specific situations — it is better tolerated in patients with certain patterns of portal vein involvement, it causes less post-procedure liver damage in patients with limited liver reserve, and it can be used in situations where TACE is technically challenging. It is available at major Indian cancer centres including Medanta, Apollo, and Fortis, and represents one of the more specialised interventional oncology capabilities that distinguishes leading Indian centres from smaller facilities.

Cost of TARE / Y-90 radioembolisation in India — 2026:

Single TARE procedure: $15,000 to $22,000. The higher cost compared to TACE reflects the cost of the Y-90 microspheres themselves, which are produced through a complex manufacturing process.

Ablation — RFA and MWA — For Small Tumours

For small HCC tumours — typically less than 3 centimetres — that are located in accessible positions within the liver, thermal ablation offers a minimally invasive alternative to surgical resection with comparable local control rates for appropriately selected tumours.

Radiofrequency ablation (RFA) uses heat generated by radiofrequency energy delivered through a needle inserted directly into the tumour — either through the skin under imaging guidance, or laparoscopically, or at the time of open surgery — to destroy the tumour cells. Microwave ablation (MWA) works on a similar principle using microwave energy rather than radiofrequency, and is increasingly preferred because it achieves higher temperatures, faster ablation times, and better results in tumours close to blood vessels.

Cost of thermal ablation in India — 2026:

Percutaneous RFA or MWA (image-guided, through the skin): $3,000 to $5,500. Laparoscopic ablation: $5,000 to $8,000.

Systemic Therapy — Targeted Therapy and Immunotherapy for Advanced HCC

For patients with advanced HCC — BCLC stage C disease involving vascular invasion or distant spread — systemic therapy is the primary treatment approach. The systemic therapy landscape for HCC has changed dramatically in the last five years.

Sorafenib was for many years the only approved systemic therapy for advanced HCC. It is a targeted therapy that works by blocking the signals driving tumour growth and the formation of new blood vessels within the tumour. It extends median survival in advanced HCC compared to placebo, but its absolute benefit is modest and its side effects — hand-foot skin reaction, diarrhoea, fatigue, and hypertension — can significantly affect quality of life.

Lenvatinib is a newer targeted agent that has shown superior or equivalent outcomes to sorafenib in first-line advanced HCC treatment, with a somewhat different side effect profile, and is now offered alongside sorafenib as a first-line option at Indian centres following international guidelines.

Atezolizumab plus bevacizumab — a combination of immunotherapy and anti-angiogenic targeted therapy — has become the preferred first-line treatment for advanced HCC at major Indian cancer centres following landmark clinical trial data showing superior survival outcomes compared to sorafenib. This combination represents the most significant advance in systemic HCC treatment in two decades and is available at Indian hospitals at dramatically lower cost than in Western markets.

Cost of systemic therapy for advanced HCC in India — 2026:

Sorafenib (per month, generic): $200 to $400. Lenvatinib (per month, generic): $300 to $600. Atezolizumab plus bevacizumab combination (per 3-week cycle): $2,500 to $5,000.

The Role of Hepatitis B Treatment During and After Liver Cancer Treatment

For Ghanaian patients with HCC arising in the context of chronic hepatitis B infection — which represents the majority of Ghanaian HCC patients — antiviral treatment for hepatitis B is not just relevant background management. It is an active and important component of the overall treatment plan.

Active hepatitis B viral replication during cancer treatment — particularly during chemotherapy, TACE, or immunosuppression after transplantation — can cause dangerous hepatitis B reactivation, a sudden severe flare of hepatitis B activity that can cause acute liver failure. Preventing reactivation requires antiviral therapy — most commonly tenofovir or entecavir — started before cancer treatment begins and continued throughout and after it.

Beyond preventing reactivation, effective hepatitis B treatment during the cancer treatment period preserves liver function, which is critical for tolerating the treatment itself and for recovery after it. Indian hepatologists and oncologists are experienced in managing hepatitis B in the context of liver cancer treatment and will ensure that antiviral therapy is appropriately prescribed and monitored as part of the overall management plan.

Cost of hepatitis B antiviral therapy in India — 2026:

Generic tenofovir (per month): $5 to $15. Generic entecavir (per month): $10 to $25. These are among the most affordable essential medicines available anywhere in the world, and their inclusion in the treatment plan adds negligible cost while providing critical protection against reactivation.

What the Treatment Journey Looks Like for a Ghanaian Liver Cancer Patient

Pre-travel — one to two weeks. You share your medical reports — CT or MRI of the liver, AFP level, hepatitis B viral load, liver function tests, and any biopsy report if available — with our team. Within 48 hours a hepatobiliary oncologist reviews them and provides a written opinion covering staging, treatment recommendation, and cost estimate. Visa application begins immediately after hospital recommendation and invitation letter are confirmed.

Arrival and workup — week one. You arrive in India, are collected from the airport, and begin the pre-treatment workup. This includes a high-quality contrast-enhanced MRI of the liver if not already available, CT of the chest and abdomen for complete staging, liver function assessment, hepatitis B viral load measurement, and pre-treatment blood tests. For surgical or transplant candidates, a detailed assessment of liver volume and function is performed using specialised imaging.

Treatment — week two onwards. The timing and nature of treatment depends on the approach chosen. Surgical resection typically takes place in week two or three after pre-operative clearance. TACE is scheduled within the first two weeks of arrival. Transplant evaluation for living donor transplantation involves evaluation of both patient and donor before a transplant date is confirmed — this process typically takes two to four weeks. Systemic therapy can begin once staging is complete and the treatment plan is confirmed.

Duration of stay. Resection patients typically stay five to seven weeks covering surgery, ICU, ward recovery, and post-operative monitoring. TACE patients typically stay ten to fourteen days per session, and multiple sessions are spaced two to three months apart — meaning many patients make multiple trips to India rather than a single extended stay. Transplant patients stay eight to twelve weeks in India after the transplant procedure, with close post-transplant monitoring required before it is safe to travel home.

Realistic total budget for common scenarios — 2026:

Single TACE procedure including one week's stay: Medical $4,500 to $7,000. Living costs for two weeks $2,000 to $3,500. Flights $1,400 to $2,800. Total per trip $8,000 to $13,000.

Liver resection including five weeks' stay: Medical $10,000 to $17,000. Living costs five weeks $4,000 to $7,000. Flights $1,400 to $2,800. Total $15,000 to $27,000.

Living donor liver transplant including ten weeks' stay: Medical $38,000 to $57,000. Living costs ten weeks $7,000 to $12,000. Flights for patient and donor $2,800 to $5,000. Total $48,000 to $74,000.

Frequently Asked Questions From Ghanaian Liver Cancer Patients

My AFP is very high — over 1000. Does that mean the cancer has spread?

A very high AFP is associated with more advanced or aggressive HCC but does not by itself confirm distant spread. Staging requires imaging — a contrast-enhanced CT or MRI of the liver combined with imaging of the chest and other organs. Share your imaging reports with us along with your AFP level and a specialist will give you an accurate staging assessment.

I have cirrhosis as well as liver cancer. Does that mean I cannot have surgery?

Not necessarily. The decision about surgical eligibility in cirrhotic patients depends on the degree of liver function impairment — measured by the Child-Pugh score and other assessments — rather than the presence of cirrhosis alone. Many patients with compensated cirrhosis (Child-Pugh A) are good candidates for limited liver resection. Patients with more significant liver function impairment may be better candidates for transplantation — which removes the cirrhotic liver entirely — or for interventional approaches like TACE. An Indian hepatobiliary specialist will assess your specific liver function status and give you an honest opinion on which options are safe and appropriate.

My doctor in Ghana says I am not a candidate for any treatment. Should I still get a second opinion?

Yes — absolutely and without hesitation. The assessment of liver cancer treatment eligibility requires specialised hepatobiliary oncology expertise combined with high-quality imaging and liver function assessment that may not always be available in Ghana. We have seen numerous cases where patients told they had no treatment options received a second opinion from an Indian specialist that identified viable treatment pathways. Share your reports with us before accepting a conclusion of no treatment options.

Can my brother travel from Ghana to donate part of his liver?

Yes. Living donor liver transplantation with a family member donor who travels from Ghana to India is feasible and is something our team has supported before. The donor undergoes a comprehensive evaluation in India to confirm they are a suitable and safe donor before any donation proceeds. The donor surgery and the recipient transplant take place simultaneously at the Indian hospital. We coordinate the logistics for both patient and donor travel and hospital admission.

I have hepatitis B as well as liver cancer. Will the treatment team manage both?

Yes. Indian hepatobiliary oncologists are entirely accustomed to managing HCC in the context of chronic hepatitis B infection. Antiviral therapy will be prescribed before cancer treatment begins, continued throughout, and maintained after treatment to prevent reactivation and to protect the remaining liver. The management of hepatitis B is integrated into the overall treatment plan rather than treated as a separate issue.

Share Your Reports Today — A Liver Cancer Specialist Will Review Them Within 48 Hours

If you or a family member has received a liver cancer diagnosis in Ghana — or if you have chronic hepatitis B and have been told that imaging shows a suspicious liver mass — the most important step you can take right now is to share your reports with our team.

Send us your CT or MRI report, your AFP level, your hepatitis B viral load and liver function tests, and any other investigations you have had done. Within 48 hours a hepatobiliary oncologist in India will review your case and provide a written opinion covering your diagnosis and staging, the treatment options that are safe and appropriate for your specific situation, the realistic outcomes associated with each option, and a detailed cost estimate.

There is no charge for this review. There is no obligation to travel. There is no pressure of any kind.

Liver cancer — particularly when it arises against the background of hepatitis B and cirrhosis — is a disease that requires specialist expertise to manage well. That expertise exists in India, it is accessible to Ghanaian patients, and it is available at costs that make treatment a realistic possibility rather than an impossible aspiration.

Reach us on WhatsApp or through the contact form on this page. We are here every day because we understand that with liver cancer, every week of delay has consequences — and the right treatment, started promptly, makes a measurable difference to what is possible.

```

Visit our full guide on [cancer treatment in India for Ghana](https://treatcancerinindia.com/cancer-treatment-india-for-ghana)

---